- Volume Zscore is a recent 2 week high. A recent surge of ZScore means trading activities is accelerating at a record speed.
- MACD is crossing MACD signal line at 0.1. MACD crossing signal line is bullish signal.
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
“Efficacy is likely the same,” Raymond James analyst Steven Seedhouse surmises. A surer comparison will become possible when both trials report detailed results in medical journals.
Pfizer stock jumped in early November after the pharma company's coronavirus vaccine proved 90% effective in a final-phase study. But if the pharmaceutical company's stock a buy now?
Theravance (TBPH) falls more than 13% as it reports wider-than-expected loss for the third quarter of 2020. Revenues meet estimates.
The first evidence of strong effectiveness in the pivotal trial of the Covid-19 vaccine developed by (PFE) and (BNTX) comes at a lucky time for hunkered-down humans, as well as for those companies’ investors. The timing of the Monday announcement is less opportune for rival vaccine developers and for President Donald Trump. If a final readout merits emergency authorization, the Pfizer team aims to make 50 million doses by year-end.
We're definitely into long term investing, but some companies are simply bad investments over any time frame. We...
Pharma company Mylan's 3Q GAAP earnings of $0.36 per share declined 2.7% year-over-year and missed the consensus estimates of $1.16. However, its adjusted net earnings grew 12% year-over-year to $679.7 million, driven by higher gross margins. 3Q revenues of $2.97 billion improved marginally from the year-ago quarter but missed analysts’ expectations of $3 billion.During the 3Q conference call, Mylan (MYL) announced that its merger with Pfizer’s Upjohn medicines business will close on Nov. 16 aft...
Mylan (MYL) beats on Q3 earnings but misses on sales. The company is all set to merge with Pfizer's Upjohn business later in the month.